Obinutuzumab plus chemotherapy showed more durable efficacy, safety, and longer progression-free survival for patients with untreated follicular lymphoma.
Researchers aimed to determine whether the addition of radiotherapy was associated with a risk for adverse events among patients treated with ICIs.
Testing without the traditional office visits and counseling poses no additional stress to women.
Promising follow-up data on safety and efficacy of fixed-duration venetoclax-obinutuzumab for patients with untreated CLL.
In this study, skeletal muscle mass, as well as subcutaneous and visceral adiposity, were measured using CT imaging performed at baseline at the level of the L3 vertebrae.
Early detection of malnourishment in patients with gastric and esophageal adenocarcinoma identified as a strategy for improving outcomes for these patients.
Physicians noted that patients receiving best supportive care were more likely to be interested in low-intensity treatments if the risk for side effects was lower.
Results of a single-center retrospective study revealed that patients with darker pigmented skin frequently experienced irCAEs, therefore, increased surveillance is needed in SOC patients.
Structured palliative care can ensure these patients and their caregivers have an optimal experience that does not hinder trial outcomes.
Researchers reported long-term follow up from the first clinical trial of anti-CD19 CAR T cells that revealed responses against lymphoma.